. . . "\u0158eh\u00E1k, Zden\u011Bk" . . "Langerhans cell histiocytosis; lenalidomide; 2-chlorodeoxyadenosine"@en . "10"^^ . . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "Lenalidomid indukoval l\u00E9\u010Debnou odpov\u011B\u010F u pacienta s agresivn\u00ED multisyst\u00E9movou formou histiocyt\u00F3zy z Langerhansov\u00FDch bun\u011Bk (LCH), rezistentn\u00ED ke 2-chlorodeoxyadenosinu a \u010Dasn\u011B relabuj\u00EDc\u00ED po vysokod\u00E1vkovan\u00E9 chemoterapii BEAM s autologn\u00ED transplantac\u00ED kmenov\u00FDch hemopoetick\u00FDch bun\u011Bk"@cs . . "Lenalidomid indukoval l\u00E9\u010Debnou odpov\u011B\u010F u pacienta s agresivn\u00ED multisyst\u00E9movou formou histiocyt\u00F3zy z Langerhansov\u00FDch bun\u011Bk (LCH), rezistentn\u00ED ke 2-chlorodeoxyadenosinu a \u010Dasn\u011B relabuj\u00EDc\u00ED po vysokod\u00E1vkovan\u00E9 chemoterapii BEAM s autologn\u00ED transplantac\u00ED kmenov\u00FDch hemopoetick\u00FDch bun\u011Bk"@cs . . "Lenalidomid indukoval l\u00E9\u010Debnou odpov\u011B\u010F u pacienta s agresivn\u00ED multisyst\u00E9movou formou histiocyt\u00F3zy z Langerhansov\u00FDch bun\u011Bk (LCH), rezistentn\u00ED ke 2-chlorodeoxyadenosinu a \u010Dasn\u011B relabuj\u00EDc\u00ED po vysokod\u00E1vkovan\u00E9 chemoterapii BEAM s autologn\u00ED transplantac\u00ED kmenov\u00FDch hemopoetick\u00FDch bun\u011Bk" . "Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chlorodeoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation"@en . . . "RIV/00209805:_____/12:#0000384!RIV13-MZ0-00209805" . "2"^^ . "http://www.prolekare.cz/vnitrni-lekarstvi-clanek/lenalidomid-indukoval-lecebnou-odpoved-u-pacienta-s-agresivni-multisystemovou-formou-histiocytozy-z-langerhansovych-37126" . "CZ - \u010Cesk\u00E1 republika" . "I, P(LC06027), P(NS10408), P(NT11154), P(NT12215), Z(MZ0MOU2005)" . . . "Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chlorodeoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation"@en . . . . "58" . . "RIV/00209805:_____/12:#0000384" . "Popisujeme pacienta s LCH, kter\u00E1 zp\u016Fsobila generalizovanou lymfadenopatii, infiltrovala plicn\u00ED parenchym a k\u016F\u017Ei. Proto byla l\u00E9\u010Dba zah\u00E1jena sb\u011Brem kmenov\u00FDch krvetvorn\u00FDch bun\u011Bk z perifern\u00ED krve po aplikaci stimula\u010Dn\u00EDho re\u017Eimu (cyklofosfamid 2 g/m2 den 1 a etoposidu 200 mg/m2 den 1\u20133). N\u00E1sledovala l\u00E9\u010Dba 2-chlorodeoxyadenosinem, v prvn\u00EDch 3 cyklechv monoterapii, 5 mg/m2 s.c. den 1\u20135 v 28denn\u00EDch cyklech, v dal\u0161\u00EDch 3 cyklech v kombinaci s cyklofosfamidem, 150 mg/m2 den 1\u20135 a metylprednisolonem 250 mg den 1\u20135. Po 2 m\u011Bs\u00EDc\u00EDch od ukon\u010Den\u00ED l\u00E9\u010Dby v\u0161ak nemoc relabovala. Tato \u010Dasn\u00E1 recidiva byla l\u00E9\u010Dena 4 cykly chemoterapie CHOEP (cyklofosfamid, doxorubicin, vinkristin, etoposid, prednison). Po 4. cyklu CHOEP n\u00E1sledovala vysokod\u00E1vkovan\u00E1 chemoterapie BEAM (BCNU, cytosin-arabinosid, etoposid, melfalan) s transplantac\u00ED autologn\u00EDch kmenov\u00FDch bun\u011Bk. Dle kontroln\u00EDho PET-CT bylo po t\u00E9to l\u00E9\u010Db\u011B dosa\u017Eeno kompletn\u00ED remise. Progrese byla dokumentov\u00E1na pomoc\u00ED PET-CT vy\u0161et\u0159en\u00ED. V r\u00E1mci 4. linie l\u00E9\u010Dby byl pod\u00E1n lenalidomid 25 mg denn\u011B po dobu 21 dn\u00ED v 28denn\u00EDch cyklech a 1kr\u00E1t t\u00FDdn\u011B dexametazon 20 mg. Po 4. cyklu l\u00E9\u010Dby lenalidomidem bylo provedeno kontroln\u00ED PET-CT vy\u0161et\u0159en\u00ED. Dle CT zobrazen\u00ED do\u0161lo k v\u00FDrazn\u00E9mu (o > 50 %) zmen\u0161en\u00ED uzlin. Dle PET hodnocen\u00ED do\u0161lo k v\u00FDrazn\u00E9mu poklesu akumulace fluorodeoxygluk\u00F3zy v posti\u017Een\u00FDch uzlin\u00E1ch i v kostn\u00EDch lo\u017Eisc\u00EDch. Dle HRCT vymizely plicn\u00ED nodularity. U pacienta poklesly hodnoty CRP v pr\u016Fb\u011Bhu l\u00E9\u010Dby a vystoupila hodnota hemoglobinu ze 110 na 141 g/l. Tak\u017Ee po 4 cyklech bylo dosa\u017Eeno parci\u00E1ln\u00ED remise. Od 6. cyklu byl k dvojkombinaci lenalidomid a dexametazon p\u0159id\u00E1n etoposid (100 mg i.v. ) ve dnech 22, 23 a 24 v\u00FD\u0161e uveden\u00E9ho 28denn\u00EDho cyklu. P\u0159id\u00E1n\u00ED etoposidu d\u00E1le v\u00FDrazn\u011B prohloubilo l\u00E9\u010Debnou odpov\u011B\u010F." . "Koukalov\u00E1, Renata" . "Lenalidomid indukoval l\u00E9\u010Debnou odpov\u011B\u010F u pacienta s agresivn\u00ED multisyst\u00E9movou formou histiocyt\u00F3zy z Langerhansov\u00FDch bun\u011Bk (LCH), rezistentn\u00ED ke 2-chlorodeoxyadenosinu a \u010Dasn\u011B relabuj\u00EDc\u00ED po vysokod\u00E1vkovan\u00E9 chemoterapii BEAM s autologn\u00ED transplantac\u00ED kmenov\u00FDch hemopoetick\u00FDch bun\u011Bk" . "Adam, Zden\u011Bk" . . . "0042-773X" . . "We describe a patient with LCH manifesting with generalized lymphadenopathy and infiltrating the pulmonary parenchyma and skin. Therefore, therapy started with the application of stimulation regimen (cyclophosphamide 2 g/m2 on day 1 and etoposide 200 mg/m2 on days 1\u20133) followed by collection of peripheral blood stem cells. Then, treatment with 2-chlorodeoxyadenosine, the first 3 cycles as monotherapy of 5 mg/m2 SC on days 1\u20135 in 28-day cycles, the next 3 cycles in combination with cyclophosphamide 150 mg/m2 on days 1\u20135 and methylprednisolone 250 mg on days 1\u20135, was used. However, the disease relapsed 2 months after completion of the therapy. This early relapse was treated with 4 cycles of CHOEP chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone). Following the 4th cycle of CHOEP, high-dose BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan) with autologous stem cell transplantation were administered. According to the follow-up PET-CT examination, this treatment resulted in complete disease remission. The progression was documented on PET-CT scanning. Lenalidomide 25 mg daily for 21 days in 28-day cycles with dexamethasone 20 mg once a week were administered as the 4th line treatment. After the 4th cycle of lenalidomide, PET-CT was performed, where the CT component suggested a significant reduction (more than 50%) in the size of the lymph nodes and the PET component showed substantial reduction in fluorodeoxyglucose accumulation in the affected lymph nodes as well as in the bone lesions. HRCT showed disappearance of pulmonary nodules. During the treatment, CRP levels declined and hemoglobin rose from 110 to 141 g/l, i.e. partial remission was achieved after 4 cycles. Etoposide (100 mg IV) was added to lenalidomide and dexamethasone on days 22, 23 and 24 of the above mentioned 28-day cycle. The added etoposide further intensified treatment response."@en . . . "Popisujeme pacienta s LCH, kter\u00E1 zp\u016Fsobila generalizovanou lymfadenopatii, infiltrovala plicn\u00ED parenchym a k\u016F\u017Ei. Proto byla l\u00E9\u010Dba zah\u00E1jena sb\u011Brem kmenov\u00FDch krvetvorn\u00FDch bun\u011Bk z perifern\u00ED krve po aplikaci stimula\u010Dn\u00EDho re\u017Eimu (cyklofosfamid 2 g/m2 den 1 a etoposidu 200 mg/m2 den 1\u20133). N\u00E1sledovala l\u00E9\u010Dba 2-chlorodeoxyadenosinem, v prvn\u00EDch 3 cyklechv monoterapii, 5 mg/m2 s.c. den 1\u20135 v 28denn\u00EDch cyklech, v dal\u0161\u00EDch 3 cyklech v kombinaci s cyklofosfamidem, 150 mg/m2 den 1\u20135 a metylprednisolonem 250 mg den 1\u20135. Po 2 m\u011Bs\u00EDc\u00EDch od ukon\u010Den\u00ED l\u00E9\u010Dby v\u0161ak nemoc relabovala. Tato \u010Dasn\u00E1 recidiva byla l\u00E9\u010Dena 4 cykly chemoterapie CHOEP (cyklofosfamid, doxorubicin, vinkristin, etoposid, prednison). Po 4. cyklu CHOEP n\u00E1sledovala vysokod\u00E1vkovan\u00E1 chemoterapie BEAM (BCNU, cytosin-arabinosid, etoposid, melfalan) s transplantac\u00ED autologn\u00EDch kmenov\u00FDch bun\u011Bk. Dle kontroln\u00EDho PET-CT bylo po t\u00E9to l\u00E9\u010Db\u011B dosa\u017Eeno kompletn\u00ED remise. Progrese byla dokumentov\u00E1na pomoc\u00ED PET-CT vy\u0161et\u0159en\u00ED. V r\u00E1mci 4. linie l\u00E9\u010Dby byl pod\u00E1n lenalidomid 25 mg denn\u011B po dobu 21 dn\u00ED v 28denn\u00EDch cyklech a 1kr\u00E1t t\u00FDdn\u011B dexametazon 20 mg. Po 4. cyklu l\u00E9\u010Dby lenalidomidem bylo provedeno kontroln\u00ED PET-CT vy\u0161et\u0159en\u00ED. Dle CT zobrazen\u00ED do\u0161lo k v\u00FDrazn\u00E9mu (o > 50 %) zmen\u0161en\u00ED uzlin. Dle PET hodnocen\u00ED do\u0161lo k v\u00FDrazn\u00E9mu poklesu akumulace fluorodeoxygluk\u00F3zy v posti\u017Een\u00FDch uzlin\u00E1ch i v kostn\u00EDch lo\u017Eisc\u00EDch. Dle HRCT vymizely plicn\u00ED nodularity. U pacienta poklesly hodnoty CRP v pr\u016Fb\u011Bhu l\u00E9\u010Dby a vystoupila hodnota hemoglobinu ze 110 na 141 g/l. Tak\u017Ee po 4 cyklech bylo dosa\u017Eeno parci\u00E1ln\u00ED remise. Od 6. cyklu byl k dvojkombinaci lenalidomid a dexametazon p\u0159id\u00E1n etoposid (100 mg i.v. ) ve dnech 22, 23 a 24 v\u00FD\u0161e uveden\u00E9ho 28denn\u00EDho cyklu. P\u0159id\u00E1n\u00ED etoposidu d\u00E1le v\u00FDrazn\u011B prohloubilo l\u00E9\u010Debnou odpov\u011B\u010F."@cs . "14"^^ . "146807" . . "1" . "[D22BE008FBA5]" . . .